Keywords : infantile

Results of Minimal Dosage Propranolol in the Management of Infantile Haemangioma

Iraqi Postgraduate Medical Journal, 2019, Volume 18, Issue 1, Pages 10-17

Infantile haemangioma one of the most common tumour of new borns , a safe and effective treatment
options are under ongoing research .
The authors show the effectiveness and safety of low dose propranolol as a method for infantile
haemangioma treatment .
In this study twenty- four patients with infantile haemangioma in different anatomical locations were
treated with oral propranolol and the result were assessed in a retrospective analysis of the results
patients were kept on 0.25 mg/kg/day for one month , then on 0.5mg/kg/day in 2 divided doses for
another one month , in the third month the dose will be increased to 1 mg/kg/day in 2 divided doses ,
then the propranolol were given in a maintenance dose ranging between 1-1.5 mg/kg/day in 2 divided
doses according to the clinical response .The duration of treatment ranging from 6-18 months as a
small dose increasing over a long time .
We had achieved excellent result in most of our patients, with reduction of size and fade of color of
hemangioma within 1 month from the initiation of treatment, when we stop the treatment no relapses
were noticed during our follow up period after finishing the course.
Propranolol is one of the safest and most effective treatment options for the infantile haemangioma
even in low dose, with lower relapse rates and minimal consecutive side effects and drawbacks.

The Role of Intralesional Bleomycin in the Management of Cutaneous Infantile Hemangioma

Iraqi Postgraduate Medical Journal, 2018, Volume 17, Issue 3, Pages 204-210

Infantile hemangioma, although often small after birth, it tends to follow a proliferative phase in which the growth may be rapid and unpredictable. Besides, its involution often takes many years to happen causing psychological problems and embarrassment to the parents as well as their child.
To evaluate the efficacy of intralesional bleomycin in the management of infantile cutaneous hemangiomas and to assess the possible side effects and complications of this treatment modality.
A prospective study done in Iraq over the period from October 2014 to December 2015, were 28 patients with cutaneous infantile hemangiomas had been treated by intralesional bleomycin injection, 0.25-0.5 unit/kg/dose, administered subcutaneously. The enrolled patients were divided depending on lesion size at time of presentation into two groups; those with hemangiomas less than 12 cm2 and others with lesions greater than 12 cm2. The lesions were measured serially and monitored with photos for follow up and documentation. Side effects were also recorded. Lesion’s response was graded into five grades according to the final size after treatment.
The mean age of the studied patients was 13.5±11.2 months (3 months to 4 years). The mean number of injections given was 3.7±0.7(3 to 5), and the mean total dose administered was 3.8±1.5 units/patient(2.5 to 9). Complete involution (>90% reduction in the size of the hemangioma) was recorded in 9(32.1%) children. Twelve (42.9%) children were reported to achieve 75-90% reduction in the size of the hemangioma. In 6(21.4%) children, there was a 50-75% reduction in the size of the lesion, and only 1 patient had <25% reduction in the size of the lesion. The mean follow up period was 5.8±2.1 months (3 to 10 months).Hyperpigmentation was the most common complication and was reported in 11(42.3%)patients.
Intralesional bleomycin is an effective option in the treatment of cutaneous infantile hemangioma